Biotech Values

[vinmantoo]

ron,

A secondary endpoint is indeed overall survival, so the question is, why isn't the overall survival data being mentioned? I was also amused by the following description in the 10K

"" The primary endpoint of the study is to determine hepatic progression free survival, which is the length of time a patient is both alive and free from any significant increase in the size of the tumor within the liver. ""

If the patient is dead, measuring tumor progression isn't a good metric.

One thing that has bugged me about DCTH investors is that they keep going from board to board making wild projections. One guy kept talking about the DCTH system being used in hepatitis B and C patients, as if it was inconsequential that those patients had compromised liver function, and the DCTH system subjects livers to massive doses of chemotherapy.